ClinicalTrials.gg
CompletedNCT05662033Updated Oct 29, 2025

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Oral AZD6793 in Healthy and Chronic Obstructive Pulmonary Disease Participants, to Assess the Relative Oral Bioavailability Between Two Formulations, and the Food Effect on the PK of AZD6793 Compared to Fasting State.

A Phase 1 interventional study of AZD6793 and Placebo in Inflammatory Diseases, sponsored by AstraZeneca. Completed at 2 sites in United Kingdom. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-29.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
93
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The purpose of the study is to assess the safety and tolerability of AZD6793 suspension following oral administration of Single Ascending Dose (SAD) [Part 1] and Multiple Ascending Dose (MAD) [Part 2] in healthy participants.

Additionally, the study will include Part 3 (bioavailability and food effect cohort) to assess the relative oral bioavailability between test formulation and oral suspension (reference formulation) as well as the effect of a high fat high calorie (HFHC) meal on the PK of AZD6793 test formulation, in comparison to fasting conditions, after a single oral dose of AZD6793 in healthy participants.

Part 4 of the study (Chronic Obstructive Pulmonary Disease [COPD] cohort) is intended to evaluate AZD6793 safety, tolerability, and PK profile for the first time in participants with moderate to severe COPD.

Part 1 (SAD), Part 2 (MAD) and Part 3 (Bioavailability and food effect cohort) have been completed. Although it was planned that 5 cohorts would be included in Part 1, only 4 cohorts (32 participants) were included. Part 3 of the study was concluded with 13 healthy participants.

Read the detailed description

Parts 1, 2, and 3 were conducted in a single center and Part 4 is conducted in 2 centers.

Part 1 of the study will comprise:

  • A Screening Period of maximum 28 days (Day -29 to Day -2)
  • A Treatment Period during which participants will be resident at the Clinical Unit from Day -1 (the day before IMP administration [Day 1]) until at least 72 hours after IMP administration. Participants will then be discharged on Day 4 if in good health and after all samples have been collected. Depending on the emerging data, the length of the stay at the Clinical Unit may be changed.
  • A Follow-up Visit within 6 ± 1 days after the IMP dose (this visit may be done later if indicated, for example, if emerging PK data indicates a longer AZD6793 half-life than was predicted).

Part 2 of the study will comprise:

  • A Screening Period of maximum 28 days (Day -29 to Day -2).
  • A Treatment Period during which participants will be resident at the Clinical Unit from Day -1 (the day before first IMP administration [Day 1]) until Day 10. participants will receive a single dose of IMP in the morning on Day 1. After a washout of at least 48 hours (depending on PK data from Part 1), participants will be dosed twice daily (12 hours apart) from Day 3 through Day 7. Participants will receive the last dose of IMP in the morning of Day 8. Participants will then be discharged on Day 10 if in good health and after all samples have been collected.
  • A Follow-up Visit within 6 ± 1 days after the last IMP dose (this visit may be done later if indicated, for example, if emerging PK data indicates a longer AZD6793 half-life than was predicted).

Part 3 of the study will comprise:

  • A Screening Period of maximum 28 days (Day -29 to Day -2).
  • A Treatment Period during which participants will be resident at the Clinical Unit from Day -1 until Day 3. Participants will be randomised on Day 1 of Visit 3 to one of 3 treatment sequences and will receive AZD6793 on Day 1 of each treatment period. Dose administration will be separated by a washout period of at least 3 days from the previous IMP dose of each treatment period.
  • A Follow-up Visit within 6 ± 1 days after the last IMP dose

Part 4 of the study will comprise:

  • A Screening Period of maximum 35 days (Day -35 to -2)
  • A Treatment Period of up to 28 days (at least 26 days) of dosing with AZD6793 or placebo. The participants will be admitted to the Clinical Unit on Day -1 and will receive single dose of AZD6793 or placebo on Day 1 and discharged from the Clinical Unit in the evening on Day 1 (12 hours post-dose).
  • A Follow--up Visit 6 ± 2 days after the last IMP dose
02

Conditions studied

  • Inflammatory Diseases

Keywords

  • IRAK4 kinase inhibitor
  • AZD6793
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Main Inclusion Criteria:

Parts 1,2 and 3:

  • Healthy male or female participants aged 18 to 55 years with suitable veins for cannulation or repeated venepuncture
  • Females must have a negative pregnancy test must not be lactating and must be either (a) non-, confirmed by defined as amenorrhea for at least 12 months; documentation of irreversible surgical sterilisation or (b) childbearing potential, i.e., fertile, following menarche and until becoming post-menopausal unless permanently sterile (Must agree to use, with their partner, an approved method of highly effective ).
  • Male participants and their female partners of childbearing potential must be willing to use highly effective contraception measures and male participants must refrain from donating sperm or fathering a child from the first day of dosing until 3 months after the last dose of IMP.
  • Have a between 18 and 30 kg/m2 inclusive and weigh at least 50 kg, at the Screening Visit.

Part 4:

  • Male and/or female participants, who have moderate to severe , and aged 40 through 80 years inclusive.
  • BMI between 18 to 44.9 kg/m2 at Screening
  • Documented history of COPD with a post-bronchodilator /FVC \<0.70 and a post-bronchodilator FEV1 ≥ 30% and \< 80% predicted at Screening
  • Documented stable inhaled treatment regimen of dual therapy or triple therapy for ≥ 3 months prior to Screening.
  • Clinically stable and free from an Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in the opinion of the Investigator for at least 35 days prior to Day 1
  • Females must have a negative pregnancy test at the Screening Visit and on admission to the Clinical Unit, must not be lactating and must be of :

    1. Non-childbearing potential confirmed at screening
    2. If considered of childbearing potential, must agree to use with their partner an approved method of highly effective contraception.
  • Male participants and their female partners of childbearing potential must be willing to use highly effective contraception measures and must refrain from donating sperm or fathering a child from first day of dosing until 3 months after last IMP dose.

Main Exclusion Criteria:

Parts 1,2 and 3:

  • History or presence of gastrointestinal, hepatic, renal, pancreatic disease or acute disease in these organs.
  • History of chronic haematologic disease.
  • Diagnosis or history of immunodeficiency or increased susceptibility to severe infection, or a infection
  • Any clinically important illness, medical/surgical procedure or trauma within 4 weeks of the first administration of IMP.
  • Positive or indeterminate QuantiFERON® Tuberculosis (TB) test at screening.
  • Any clinically important abnormalities in clinical chemistry, haematology or urinalysis results
  • Any positive result on Screening for serum surface antigen (HBsAg), antibody and (HIV).
  • Any clinically important abnormalities in rhythm, conduction or morphology of the resting (ECG) and any clinically important abnormalities in the 12 lead ECG.
  • Known or suspected history of alcohol and drug abuse in the last year.
  • Current smokers or those who have smoked or used nicotine products (including e cigarettes) within the previous 3 months.
  • History of severe allergy/ or ongoing clinically important allergy/hypersensitivity, or history of hypersensitivity to drugs with a similar chemical structure or class to AZD6793.
  • Excessive intake of caffeine containing drinks or food
  • Use of drugs with enzyme inducing properties such as St John's Wort within 3 weeks prior to the first administration of IMP.
  • Use of any prescribed or nonprescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies, mega dose vitamins (intake of 20 to 600 times the recommended daily dose) and minerals during the 2 weeks prior to the first administration of IMP or longer if the medication has a long half life
  • Plasma donation within one month of the Screening Visit or any blood donation/blood loss > 500 mL during the 3 months prior to the Screening Visit.
  • Parts 2 and 3 only: Participants who have previously received AZD6793.

Part 4:

  • Concurrent enrolment in another clinical study involving an treatment
  • Participants unable to perform reproducible spirometry according to American Thoracic Society/ European Respiratory Society [ATS/ERS] criteria at Screening
  • Any active medical condition or other reason (at Screening, Day -1, and pre-dose) that would interfere with evaluation of the investigational product or interpretation of participant safety or study results, any other clinically relevant abnormal findings on physical examination or laboratory testing at Screening
  • Positive or indeterminate QuantiFERON® TB test at Screening. Indeterminate results may be repeated during Screening.
  • Major surgery within 8 weeks prior to Screening
  • Donation of blood or blood products in excess of 500 mL within 3 months prior to Screening
  • History or current diagnosis of cancer, history of an underlying condition that predisposes the participant to infections, known history of severe reaction to any medication, history of bone marrow transplant and history of viral, bacterial or fungal infections within 4 weeks prior to randomisation
  • Receiving any immunotherapy or therapy other than within 6 months of randomisation
  • Participants taking metformin during Screening or at any time during the study
  • Any participant with active hepatitis or Human immunodeficiency virus (HIV)
  • History or presence of vitiligo or significant (in the opinion of the Investigator) skin depigmentation for any cause including drugs
  • History of clinically significant chronic/active haematology disease
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Single (Participant)
Enrollment
93 participants (actual)

Study arms

  • Experimental
    Part 1 (SAD): Cohort 1

    6 Healthy participants will receive a single oral dose A of AZD6793 and 2 healthy participants will receive placebo

    Drug: AZD6793 · Drug: Placebo

  • Experimental
    Part 1 (SAD): Cohort 2

    6 Healthy participants will receive a single oral dose B of AZD6793 and 2 healthy participants will receive placebo

    Drug: AZD6793 · Drug: Placebo

  • Experimental
    Part 1 (SAD): Cohort 3

    6 Healthy participants will receive a single oral dose C of AZD6793 and 2 healthy participants will receive placebo

    Drug: AZD6793 · Drug: Placebo

  • Experimental
    Part 1 (SAD): Cohort 4

    6 Healthy participants will receive a single oral dose D of AZD6793 and 2 healthy participants will receive placebo

    Drug: AZD6793 · Drug: Placebo

  • Experimental
    Part 1 (SAD): Cohort 5

    6 Healthy participants will receive a single oral dose E of AZD6793 and 2 healthy participants will receive placebo

    Drug: AZD6793 · Drug: Placebo

  • Experimental
    Part 2 (MAD): Cohort 1

    6 Healthy participants will receive dose W of AZD6793 and 2 healthy participants will receive placebo once daily on Day 1 and 8 and twice daily on Day 3 to Day 7

    Drug: AZD6793 · Drug: Placebo

  • Experimental
    Part 2 (MAD): Cohort 2

    6 Healthy participants will receive dose X of AZD6793 and 2 healthy participants will receive placebo once daily on Day 1 and 8 and twice daily on Day 3 to Day 7

    Drug: AZD6793 · Drug: Placebo

  • Experimental
    Part 2 (MAD): Cohort 3

    6 Healthy participants will receive dose Y of AZD6793 and 2 healthy participants will receive placebo once daily on Day 1 and 8 and twice daily on Day 3 to Day 7

    Drug: AZD6793 · Drug: Placebo

  • Experimental
    Part 2 (MAD) : Cohort 4

    6 Healthy participants will receive dose Z of AZD6793 and 2 healthy participants will receive placebo once daily on Day 1 and 8 and twice daily on Day 3 to Day 7

    Drug: AZD6793 · Drug: Placebo

  • Experimental
    Part 3: Treatment sequence 1

    Participants will receive a single oral dose of test formulation AZD6793 in fasted state, test formulation AZD6793 in fed state following reference formulation AZD6793 in fasted state once on Day 1 of each treatment period.

    Drug: AZD6793

  • Experimental
    Part 3: Treatment sequence 2

    Participants will receive a single oral dose of test formulation AZD6793 in fed state, reference formulation AZD6793 in fasted state following test formulation AZD6793 in fasted state once on Day 1 of each treatment period.

    Drug: AZD6793

  • Experimental
    Part 3: Treatment sequence 3

    Participants will receive a single oral dose of reference formulation AZD6793 in fasted state, test formulation AZD6793 in fasted state following test formulation AZD6793 in fed state once on Day 1 of each treatment period.

    Drug: AZD6793

  • Experimental
    Part 4 (COPD): Cohort 1

    10 participants with COPD will receive AZD6793 once daily and 5 participants with COPD will receive placebo

    Drug: AZD6793 · Drug: Placebo

Interventions

  • AZD6793 will be administered orally

  • DrugPlacebo

    Placebo will be administered orally

06

What researchers measure

Primary outcomes

  1. Part 1 (SAD): Number of participants with adverse events

    Safety and tolerability of AZD6793 following oral administration of SAD in healthy participants.

    Time frame: From screening up to Follow up visit (Day 6±1)

  2. Part 2 (MAD): Number of participants with adverse events

    Safety and tolerability of AZD6793 following oral administration of MAD in healthy participants.

    Time frame: From screening up to Follow up visit (Day 14±1)

  3. Part 1 (SAD): Number of participants with abnormal findings in vital signs (supine Blood Pressure (BP), pulse, respiratory rate, peripheral oxygen saturation (SpO2) and oral body temperature)

    Safety and tolerability of AZD6793 following oral administration of SAD in healthy participants.

    Time frame: From screening, Treatment Day 1 to Day 4 up to Follow up visit (Day 6±1)

  4. Part 2 (MAD): Number of participants with abnormal findings in vital signs (supine Blood Pressure (BP), pulse, respiratory rate, peripheral oxygen saturation (SpO2) and oral body temperature)

    Safety and tolerability of AZD6793 following oral administration of MAD in healthy participants.

    Time frame: From screening, Treatment Day -1 to Day 10 up to Follow up visit (Day 14±1)

  5. Part 1 (SAD): Number of participants with abnormal findings in 12 Lead electrocardiogram (ECG)

    Safety and tolerability of AZD6793 following oral administration of SAD in healthy participants.

    Time frame: From screening, Treatment Day -1 to Day 4 up to Follow up visit (Day 6±1)

  6. Part 2 (MAD): Number of participants with abnormal findings in 12 Lead electrocardiogram (ECG)

    Safety and tolerability of AZD6793 following oral administration of MAD in healthy participants.

    Time frame: From screening, Treatment Day -1 to Day 10 up to Follow up visit (Day 14±1)

  7. Part 1 (SAD): Number of participants with abnormal findings in 12 Lead Digital electrocardiogram (dECG)

    Safety and tolerability of AZD6793 following oral administration of SAD in healthy participants.

    Time frame: Day 1 to Day 3

  8. Part 2 (MAD): Number of participants with abnormal findings in 12 Lead Digital electrocardiogram (dECG)

    Safety and tolerability of AZD6793 following oral administration of MAD in healthy participants.

    Time frame: Day 1 to Day 3, Day 5, Day 8 to Day 10

  9. Part 1 (SAD): Number of participants with abnormal findings in Telemetry

    Safety and tolerability of AZD6793 following oral administration of SAD in healthy participants.

    Time frame: Day -1 to Day 3

  10. Part 2 (MAD): Number of participants with abnormal findings in Telemetry

    Safety and tolerability of AZD6793 following oral administration of MAD in healthy participants.

    Time frame: Day -1 to Day 2 and Day 8 to Day 10

  11. Part 1 (SAD): Number of participants with abnormal findings in Physical examinations

    Safety and tolerability of AZD6793 following oral administration of SAD in healthy participants.

    Time frame: From screening, Treatment Day -1 to 4 and follow up visit

  12. Part 2 (MAD): Number of participants with abnormal findings in Physical examinations

    Safety and tolerability of AZD6793 following oral administration of MAD in healthy participants.

    Time frame: From screening, Treatment Day -1 to 10 and follow up visit

  13. Part 1 (SAD): Number of participants with abnormal findings in Laboratory assessments (haematology, serum clinical chemistry, and urinalysis)

    Safety and tolerability of AZD6793 following oral administration of SAD in healthy participants.

    Time frame: From screening, Treatment Day -1, Day 2, Day 4 and Follow up visit (Day 6±1)

  14. Part 2 (MAD): Number of participants with abnormal findings in Laboratory assessments (haematology, serum clinical chemistry, and urinalysis)

    Safety and tolerability of AZD6793 following oral administration of MAD in healthy participants.

    Time frame: From screening, Treatment Day -1 to Day 10 up to Follow up visit (Day 14±1)

  15. Part 3 (Bioavailability): Maximum observed plasma (peak) drug concentration [Cmax]

    Evaluating the relative oral bioavailability between the test formulation and the reference formulation after a single oral dose of AZD6793 in healthy participants.

    Time frame: Day 1 to Day 3

  16. Part 3 (Bioavailability): Area under plasma concentration-time curve from zero to infinity [AUCinf]

    Evaluating the relative oral bioavailability between the test formulation and the reference formulation after a single oral dose of AZD6793 in healthy participants.

    Time frame: Day 1 to Day 3

  17. Part 3 (Food effect): Cmax of AZD6793

    Investigating the effect of a high fat high calorie (HFHC) meal compared to fasting conditions, on the PK of AZD6793 after a single oral dose in healthy participants.

    Time frame: Day 1 to Day 3

  18. Part 3 (Food effect): AUCinf of AZD6793

    Investigating the effect of a high fat high calorie (HFHC) meal compared to fasting conditions, on the PK of AZD6793 after a single oral dose in healthy participants.

    Time frame: Day 1 to Day 3

  19. Part 4 (COPD): Number of participants with adverse events

    Safety and tolerability of AZD6793 following oral administration repeated up to 28 days (at least 26 days) in COPD participants.

    Time frame: From screening up to Follow up visit (Day 34±2)

  20. Part 4 (COPD): Number of participants with abnormal findings in vital signs (supine Blood Pressure (BP), pulse, respiratory rate, peripheral oxygen saturation (SpO2) and oral body temperature)

    Safety and tolerability of AZD6793 following oral administration repeated up to 28 days (at least 26 days) in COPD participants.

    Time frame: From screening up to Follow up visit (Day 34±2)

  21. Part 4 (COPD): Number of participants with abnormal findings in 12 Lead electrocardiogram (ECG)

    Safety and tolerability of AZD6793 following oral administration repeated up to 28 days (at least 26 days) in COPD participants.

    Time frame: From screening up to Follow up visit (Day 34±2)

  22. Part 4 (COPD): Number of participants with abnormal findings in Physical examinations

    Safety and tolerability of AZD6793 following oral administration repeated up to 28 days (at least 26 days) in COPD participants.

    Time frame: From screening, Treatment Day -1, 1, 14, 28 and follow up visit (34±2)

  23. Part 4 (COPD): Number of participants with abnormal findings in Laboratory assessments (haematology, clinical chemistry, coagulation tests, and urinalysis)

    Safety and tolerability of AZD6793 following oral administration repeated up to 28 days (at least 26 days) in COPD participants.

    Time frame: From screening up to Follow up visit (Day 34±2)

Secondary outcomes

  1. Part 1 (SAD): Maximum observed plasma (peak) drug concentration (Cmax)

    Characterizing pharmacokinetics of AZD6793 following oral administration of SAD in healthy participants.

    Time frame: Day 1 to Day 3

  2. Part 1 (SAD): Time to reach peak or maximum observed concentration or response following drug administration (tmax)

    Characterizing pharmacokinetics of AZD6793 following oral administration of SAD in healthy participants.

    Time frame: Day 1 to Day 3

  3. Part 1 (SAD): Terminal rate constant, estimated by log linear least squares regression of the terminal part of the concentration time curve (λz)

    Characterizing pharmacokinetics of AZD6793 following oral administration of SAD in healthy participants.

    Time frame: Day 1 to Day 3

  4. Part 1 (SAD): Half life associated with terminal slope (λz) of a semi logarithmic concentration time curve ( t½λz)

    Characterizing pharmacokinetics of AZD6793 following oral administration of SAD in healthy participants.

    Time frame: Day 1 to Day 3

  5. Part 1 (SAD): Partial area under the plasma concentration time curve from time 0 to time 12 (AUC(0-12))

    Characterizing pharmacokinetics of AZD6793 following oral administration of SAD in healthy participants.

    Time frame: Day 1 to Day 3

  6. Part 1 (SAD): Partial area under the plasma concentration time curve from time 0 to time 24 (AUC(0-24))

    Characterizing pharmacokinetics of AZD6793 following oral administration of SAD in healthy participants.

    Time frame: Day 1 to Day 3

  7. Part 1 (SAD): Area under the plasma concentration curve from zero to the last quantifiable concentration (AUClast)

    Characterizing pharmacokinetics of AZD6793 following oral administration of SAD in healthy participants.

    Time frame: Day 1 to Day 3

  8. Part 1 (SAD): Area under plasma concentration time curve from zero to infinity (AUCinf)

    Characterizing pharmacokinetics of AZD6793 following oral administration of SAD in healthy participants.

    Time frame: Day 1 to Day 3

  9. Part 1 (SAD): Apparent total body clearance of drug from plasma after extravascular administration (CL/F)

    Characterizing pharmacokinetics of AZD6793 following oral administration of SAD in healthy participants.

    Time frame: Day 1 to Day 3

  10. Part 1 (SAD): Volume of distribution (apparent) at steady state following extravascular administration (based on terminal phase) (Vz/F)

    Characterizing pharmacokinetics of AZD6793 following oral administration of SAD in healthy participants.

    Time frame: Day 1 to Day 3

  11. Part 1 (SAD): Area under the plasma concentration time curve from time zero to time of last quantifiable analyte concentration divided by the dose administered (Dose normalised AUClast)

    Characterizing pharmacokinetics of AZD6793 following oral administration of SAD in healthy participants.

    Time frame: Day 1 to Day 3

  12. Part 1 (SAD): Area under the plasma concentration time curve from time zero extrapolated to infinity divided by the dose administered (Dose normalised AUCinf)

    Characterizing pharmacokinetics of AZD6793 following oral administration of SAD in healthy participants.

    Time frame: Day 1 to Day 3

  13. Part 1 (SAD): Maximum observed plasma (peak) drug concentration divided by the dose administered (Dose normalised Cmax).

    Characterizing pharmacokinetics of AZD6793 following oral administration of SAD in healthy participants.

    Time frame: Day 1 to Day 3

  14. Part 2 (MAD): Maximum observed plasma (peak) drug concentration (Cmax)

    Characterizing pharmacokinetics of AZD6793 following oral administration of MAD in healthy participants.

    Time frame: Day 1 to Day 10

  15. Part 2 (MAD): Concentration at the end of the dosing interval (Ctrough)

    Characterizing pharmacokinetics of AZD6793 following oral administration of SAD in healthy participants.

    Time frame: Day 1 to Day 10

  16. Part 2 (MAD): Temporal change parameter (TCP) assessed in urine

    Characterizing pharmacokinetics of AZD6793 following oral administration of SAD in healthy participants.

    Time frame: Day 1 and Day 8

  17. Part 2 (MAD): Time to reach peak or maximum observed concentration or response following drug administration (tmax)

    Characterizing pharmacokinetics of AZD6793 following oral administration of MAD in healthy participants.

    Time frame: Day 1 to Day 10

  18. Part 2 (MAD): Terminal rate constant, estimated by log linear least squares regression of the terminal part of the concentration time curve (λz)

    Characterizing pharmacokinetics of AZD6793 following oral administration of MAD in healthy participants.

    Time frame: Day 1 to Day 10

  19. Part 2 (MAD): Half life associated with terminal slope (λz) of a semi logarithmic concentration time curve ( t½λz)

    Characterizing pharmacokinetics of AZD6793 following oral administration of MAD in healthy participants.

    Time frame: Day 1 to Day 10

  20. Part 2 (MAD): Partial area under the plasma concentration time curve from time 0 to time 24 (AUC(0-24))

    Characterizing pharmacokinetics of AZD6793 following oral administration of MAD in healthy participants.

    Time frame: Day 1 to Day 10

  21. Part 2 (MAD): Area under the plasma concentration curve from zero to the last quantifiable concentration (AUClast)

    Characterizing pharmacokinetics of AZD6793 following oral administration of MAD in healthy participants.

    Time frame: Day 1 to Day 10

  22. Part 2 (MAD): Area under plasma concentration time curve from zero to infinity (AUCinf)

    Characterizing pharmacokinetics of AZD6793 following oral administration of MAD in healthy participants.

    Time frame: Day 1 to Day 10

  23. Part 2 (MAD): Area under plasma concentration time curve in the dosing interval t (AUCt)

    Characterizing pharmacokinetics of AZD6793 following oral administration of MAD in healthy participants.

    Time frame: Day 1 to Day 10

  24. Part 2 (MAD): Apparent total body clearance of drug from plasma after extravascular administration (CL/F)

    Characterizing pharmacokinetics of AZD6793 following oral administration of MAD in healthy participants.

    Time frame: Day 1 to Day 10

  25. Part 2 (MAD): Volume of distribution (apparent) at steady state following extravascular administration (based on terminal phase) (Vz/F)

    Characterizing pharmacokinetics of AZD6793 following oral administration of MAD in healthy participants.

    Time frame: Day 1 to Day 10

  26. Part 2 (MAD): Area under the plasma concentration time curve from time zero to time of last quantifiable analyte concentration divided by the dose administered (Dose normalised AUClast)

    Characterizing pharmacokinetics of AZD6793 following oral administration of MAD in healthy participants.

    Time frame: Day 1 to Day 10

  27. Part 2 (MAD): Area under the plasma concentration-time curve from time zero to the dosing interval t concentration divided by the dose administered (Dose normalised AUCt)

    Characterizing pharmacokinetics of AZD6793 following oral administration of MAD in healthy participants.

    Time frame: Day 1 to Day 10

  28. Part 2 (MAD): Maximum observed plasma (peak) drug concentration divided by the dose administered (Dose normalised Cmax)

    Characterizing pharmacokinetics of AZD6793 following oral administration of MAD in healthy participants.

    Time frame: Day 1 to Day 10

  29. Part 2 (MAD): Ratio of the area under the curve (Rac AUC)

    Characterizing pharmacokinetics of AZD6793 following oral administration of MAD in healthy participants.

    Time frame: Day 1 to Day 10

  30. Part 2 (MAD): Accumulation ratio based on Cmax (Rac Cmax)

    Characterizing pharmacokinetics of AZD6793 following oral administration of MAD in healthy participants.

    Time frame: Day 1 to Day 10

  31. Part 2 (MAD): Cumulative amount of unchanged drug excreted into urine from time t1 to time t2 [Ae(t1 t2)]

    Characterizing pharmacokinetics of AZD6793 following oral administration of MAD in healthy participants.

    Time frame: Day 1 and Day 8

  32. Part 2 (MAD): Cumulative amount of unchanged drug excreted into urine (Aeinf)

    Characterizing pharmacokinetics of AZD6793 following oral administration of MAD in healthy participants.

    Time frame: Day 1 and Day 8

  33. Part 2 (MAD): Renal clearance of drug from plasma (CLR) assessed in urine

    Characterizing pharmacokinetics of AZD6793 following oral administration of MAD in healthy participants.

    Time frame: Day 1 and Day 8

  34. Part 3 (Bioavailability): Cmax of AZD6793 (test Vs reference formulation)

    To assess the PK profiles of AZD6793 when administered as a test formulation versus reference formulation in healthy participants

    Time frame: Day 1 to Day 3

  35. Part 3 (Bioavailability): tmax of AZD6793 (test Vs reference formulation)

    To assess the PK profiles of AZD6793 when administered as a test formulation versus reference formulation in healthy participants

    Time frame: Day 1 to Day 3

  36. Part 3 (Bioavailability): λz of AZD6793 (test Vs reference formulation)

    To assess the PK profiles of AZD6793 when administered as a test formulation versus reference formulation in healthy participants

    Time frame: Day 1 to Day 3

  37. Part 3 (Bioavailability): t½λz of AZD6793 (test Vs reference formulation)

    To assess the PK profiles of AZD6793 when administered as a test formulation versus reference formulation in healthy participants

    Time frame: Day 1 to Day 3

  38. Part 3 (Bioavailability): AUC(0-12) of AZD6793 (test Vs reference formulation)

    To assess the PK profiles of AZD6793 when administered as a test formulation versus reference formulation in healthy participants

    Time frame: Day 1 to Day 3

  39. Part 3 (Bioavailability): AUC(0-24) of AZD6793 (test Vs reference formulation)

    To assess the PK profiles of AZD6793 when administered as a test formulation versus reference formulation in healthy participants

    Time frame: Day 1 to Day 3

  40. Part 3 (Bioavailability): AUClast of AZD6793 (test Vs reference formulation)

    To assess the PK profiles of AZD6793 when administered as a test formulation versus reference formulation in healthy participants

    Time frame: Day 1 to Day 3

  41. Part 3 (Bioavailability): AUCinf of AZD6793 (test Vs reference formulation)

    To assess the PK profiles of AZD6793 when administered as a test formulation versus reference formulation in healthy participants

    Time frame: Day 1 to Day 3

  42. Part 3 (Bioavailability): CL/F of AZD6793 (test Vs reference formulation)

    To assess the PK profiles of AZD6793 when administered as a test formulation versus reference formulation in healthy participants

    Time frame: Day 1 to Day 3

  43. Part 3 (Bioavailability): Vz/F of AZD6793 (test Vs reference formulation)

    To assess the PK profiles of AZD6793 when administered as a test formulation versus reference formulation in healthy participants

    Time frame: Day 1 to Day 3

  44. Part 3 (Bioavailability) :Relative bioavailability calculated as test AUC/reference AUC [Frel AUC]

    To assess the PK profiles of AZD6793 when administered as a test formulation versus reference formulation in healthy participants

    Time frame: Day 1 to Day 3

  45. Part 3 (Bioavailability): Relative bioavailability calculated as test Cmax/reference Cmax [Frel Cmax]

    To assess the PK profiles of AZD6793 when administered as a test formulation versus reference formulation in healthy participants

    Time frame: Day 1 to Day 3

  46. Part 3 (Food effect): Cmax of AZD6793 (under fasted and fed state)

    To examine the PK profiles of AZD6793 test formulation under fasted and fed (after intake of a HFHC meal) conditions in healthy participants.

    Time frame: Day 1 to Day 3

  47. Part 3 (Food effect): tmax of AZD6793 (under fasted and fed state)

    To examine the PK profiles of AZD6793 test formulation under fasted and fed (after intake of a HFHC meal) conditions in healthy participants.

    Time frame: Day 1 to Day 3

  48. Part 3 (Food effect): λz of AZD6793 (under fasted and fed state)

    To examine the PK profiles of AZD6793 test formulation under fasted and fed (after intake of a HFHC meal) conditions in healthy participants.

    Time frame: Day 1 to Day 3

  49. Part 3 (Food effect): t½λz of AZD6793 (under fasted and fed state)

    To examine the PK profiles of AZD6793 test formulation under fasted and fed (after intake of a HFHC meal) conditions in healthy participants.

    Time frame: Day 1 to Day 3

  50. Part 3 (Food effect): AUC(0-12) of AZD6793 (under fasted and fed state)

    To examine the PK profiles of AZD6793 test formulation under fasted and fed (after intake of a HFHC meal) conditions in healthy participants.

    Time frame: Day 1 to Day 3

  51. Part 3 (Food effect): AUC(0-24) of AZD6793 (under fasted and fed state)

    To examine the PK profiles of AZD6793 test formulation under fasted and fed (after intake of a HFHC meal) conditions in healthy participants.

    Time frame: Day 1 to Day 3

  52. Part 3 (Food effect): AUClast of AZD6793 (under fasted and fed state)

    To examine the PK profiles of AZD6793 test formulation under fasted and fed (after intake of a HFHC meal) conditions in healthy participants.

    Time frame: Day 1 to Day 3

  53. Part 3 (Food effect): AUCinf of AZD6793 (under fasted and fed state)

    To examine the PK profiles of AZD6793 test formulation under fasted and fed (after intake of a HFHC meal) conditions in healthy participants.

    Time frame: Day 1 to Day 3

  54. Part 3 (Food effect): CL/F of AZD6793 (under fasted and fed state)

    To examine the PK profiles of AZD6793 test formulation under fasted and fed (after intake of a HFHC meal) conditions in healthy participants.

    Time frame: Day 1 to Day 3

  55. Part 3 (Food effect): Vz/F of AZD6793 (under fasted and fed state)

    To examine the PK profiles of AZD6793 test formulation under fasted and fed (after intake of a HFHC meal) conditions in healthy participants.

    Time frame: Day 1 to Day 3

  56. Part 3 (Food effect) :Frel AUC of AZD6793 (under fasted and fed state)

    To examine the PK profiles of AZD6793 test formulation under fasted and fed (after intake of a HFHC meal) conditions in healthy participants.

    Time frame: Day 1 to Day 3

  57. Part 3 (Food effect): Frel Cmax of AZD6793 (under fasted and fed state)

    To examine the PK profiles of AZD6793 test formulation under fasted and fed (after intake of a HFHC meal) conditions in healthy participants.

    Time frame: Day 1 to Day 3

  58. Part 4 (COPD): Maximum observed plasma (peak) drug concentration (Cmax)

    Characterizing the pharmacokinetic profile of AZD6793 following oral repeated administration up to 28 days (at least 26 days) in COPD participants

    Time frame: Day 1 to Day 28

  59. Part 4 (COPD): Concentration at the end of the dosing interval (Ctrough)

    Characterizing the pharmacokinetic profile of AZD6793 following oral repeated administration up to 28 days (at least 26 days) in COPD participants

    Time frame: Day 1 to Day 28

  60. Part 4 (COPD): Temporal change parameter (TCP) assessed in urine

    Characterizing the pharmacokinetic profile of AZD6793 following oral repeated administration up to 28 days (at least 26 days) in COPD participants

    Time frame: Day 1 and Day 8

  61. Part 4 (COPD): Time to reach peak or maximum observed concentration or response following drug administration (tmax)

    Characterizing the pharmacokinetic profile of AZD6793 following oral repeated administration up to 28 days (at least 26 days) in COPD participants

    Time frame: Day 1 to Day 28

  62. Part 4 (COPD): Terminal rate constant, estimated by log linear least squares regression of the terminal part of the concentration time curve (λz)

    Characterizing the pharmacokinetic profile of AZD6793 following oral repeated administration up to 28 days (at least 26 days) in COPD participants

    Time frame: Day 1 to Day 28

  63. Part 4 (COPD): Half life associated with terminal slope (λz) of a semi logarithmic concentration time curve ( t½λz)

    Characterizing the pharmacokinetic profile of AZD6793 following oral repeated administration up to 28 days (at least 26 days) in COPD participants

    Time frame: Day 1 to Day 28

  64. Part 4 (COPD): Partial area under the plasma concentration time curve from time 0 to time 12 (AUC(0-12))

    Characterizing the pharmacokinetic profile of AZD6793 following oral repeated administration up to 28 days (at least 26 days) in COPD participants

    Time frame: Day 1 to Day 28

  65. Part 4 (COPD): Partial area under the plasma concentration time curve from time 0 to time 24 (AUC(0-24))

    Characterizing the pharmacokinetic profile of AZD6793 following oral repeated administration up to 28 days (at least 26 days) in COPD participants

    Time frame: Day 1 to Day 28

  66. Part 4 (COPD): Area under the plasma concentration curve from zero to the last quantifiable concentration (AUClast)

    Characterizing the pharmacokinetic profile of AZD6793 following oral repeated administration up to 28 days (at least 26 days) in COPD participants

    Time frame: Day 1 to Day 28

  67. Part 4 (COPD): Area under plasma concentration time curve from zero to infinity (AUCinf)

    Characterizing the pharmacokinetic profile of AZD6793 following oral repeated administration up to 28 days (at least 26 days) in COPD participants

    Time frame: Day 1 to Day 28

  68. Part 4 (COPD): Area under plasma concentration time curve in the dosing interval t (AUCt)

    Characterizing the pharmacokinetic profile of AZD6793 following oral repeated administration up to 28 days (at least 26 days) in COPD participants

    Time frame: Day 1 to Day 28

  69. Part 4 (COPD): Apparent total body clearance of drug from plasma after extravascular administration (CL/F)

    Characterizing the pharmacokinetic profile of AZD6793 following oral repeated administration up to 28 days (at least 26 days) in COPD participants

    Time frame: Day 1 to Day 28

  70. Part 4 (COPD): Volume of distribution (apparent) at steady state following extravascular administration (based on terminal phase) (Vz/F)

    Characterizing the pharmacokinetic profile of AZD6793 following oral repeated administration up to 28 days (at least 26 days) in COPD participants

    Time frame: Day 1 to Day 28

  71. Part 4 (COPD): Ratio of the area under the curve (Rac AUC)

    Characterizing the pharmacokinetic profile of AZD6793 following oral repeated administration up to 28 days (at least 26 days) in COPD participants

    Time frame: Day 1 to Day 28

  72. Part 4 (COPD): Accumulation ratio based on Cmax (Rac Cmax)

    Characterizing the pharmacokinetic profile of AZD6793 following oral repeated administration up to 28 days (at least 26 days) in COPD participants

    Time frame: Day 1 to Day 28

07

Study locations

2 sites
  • Research Site
    Harrow, HA1 3UJ, United Kingdom
  • Research Site
    Wythenshawe, M23 9QZ, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2022 to primary completion in Oct 2024, 22 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2022
First posted
Dec 22, 2022
StartActual
Dec 5, 2022
Primary completionActual
Oct 29, 2024
CompletionActual
Oct 29, 2024
Last update
Oct 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05662033
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Dec 22, 2022
Start date
Dec 5, 2022
Primary completion
Oct 29, 2024
Completion
Oct 29, 2024
Last update
Oct 29, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD6793

Start the discussion